| Literature DB >> 34366706 |
Mario Jug1, Bo Kyeong Yoon2, Joshua A Jackman2.
Abstract
Cyclodextrins (CDs) are biocompatible, cyclic oligosaccharides that are widely used in various industrial applications and have intriguing interfacial science properties. While CD molecules typically have low surface activity, they are capable of stabilizing emulsions by inclusion complexation of oil-phase components at the oil/water interface, which results in Pickering emulsion formation. Such surfactant-free formulations have gained considerable attention in recent years, owing to their enhanced physical stability, improved tolerability, and superior environmental compatibility compared to conventional, surfactant-based emulsions. In this review, we critically describe the latest insights into the molecular mechanisms involved in CD stabilization of Pickering emulsions, including covering practical aspects such as methods to prepare CD-based Pickering emulsions, lipid encapsulation, and relevant stability issues. In addition, the rheological and textural features of CD-based Pickering emulsions are discussed and particular attention is focused on promising examples for drug delivery, cosmetic, and nutraceutical applications. The functionality of currently developed CD-based Pickering emulsions is also summarised, including examples such as antifungal uses, and we close by discussing emerging possibilities to utilize the molecular encapsulation of CD-based emulsions for translational medicine applications in the antiviral and antibacterial spaces.Entities:
Keywords: Antifungals; Cyclodextrin; Drug delivery; Lipids; Pickering emulsion; Stability
Year: 2021 PMID: 34366706 PMCID: PMC8330820 DOI: 10.1007/s10847-021-01097-z
Source DB: PubMed Journal: J Incl Phenom Macrocycl Chem ISSN: 1388-3127 Impact factor: 1.633
Fig. 1Representative structure of a Pickering emulsion. Depending on the characteristics of the stabilising particles, O/W or W/O type emulsions can be formed. Particles dominantly wetted with the water phase (three-phase angle, θ < 90°) will form O/W type emulsions, while particles dominantly wetted by the oil phase (θ > 90°) will form W/O type emulsions
Fig. 2Mechanism of Pickering emulsion stabilisation with CDs: A formation of inclusion complexes at the O/W interface at low CD concentration and/or early stages of formation; B crystallisation of oil/CD complexes at the O/W interface occurring at high CD concentration and/or longer interaction time; and C emulsion stabilisation with CD/PEG hydrogel
Overview of Pickering emulsions stabilised with CDs that were developed for delivery of active pharmaceutical ingredients or nutraceuticals
| Active ingredient | Cyclodextrin | Emulsion | References | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Type | Concentration | Aqueous phase | Oil phase | Type | Emulsification method | Droplet size | Consistency | Stability | ||
| - | βCD | 0–40% (w/w) | Purified water (70–30%, w/w) | Soybean oil (30–70%, w/w) | O/W | Rotor/stator homogenizer operating at 10,000 rpm for 5 min | NA | NA | NA |
[
|
Squalene (30–70%, w/w) | O/W | |||||||||
Liquid paraffin (30–70%, w/w) | O/W | |||||||||
Camphor (0.25%, w/w) | αCD βCD γCD | 0.1 mol/L | Purified water (20%, w/w) | O 1 – 30% (w/w) of soybean oil O 2 – 5% (w/w) of candelilla wax and 45% (w/w) of soybean oil | O 1 /W/O 2 | Rotor/stator homogenizer operating at 2,000 rpm for 1 min | NA | NA | Temperature and drug dependent, blank emulsion with αCD is the most stable |
[
|
Econazole nitrate (1%, w/w) | αCD βCD γCD | 13.93% (w/w) | Purified water (42.43%, w/w) containing 0.21% (w/w) of benzoic acid as preservative | Liquid paraffin or isopropyl myristate (42.43%, w/w) | O/W | Rotor/stator homogenizer operating at 11,500 rpm for 1 min | 9–16.1 μm, depending on the composition | Fluid or cream, depending on the composition | Better stability for emulsion formed with isopropyl myristate, γCD produced the most stable systems |
[
|
Bupivacaine hydrochloride (3%, w/w) | αCD βCD | 5% (w/w) | Purified water | Medium-chain triglycerides, castor oil, isopropyl myristate, diethyl sebaceate, limonene, or octyl salicylate (40%, w/w) | O/W | Rotor/stator homogenizer operating at (20,000 rpm for 2 min) | 3.0–28.3 μm, depending on the composition | Liquid or cream | Dependent upon composition |
[
|
Captopril (5%, w/w) | αCD βCD γCD | 15 – 25% (w/w) | Purified water (42–46%, w/w) | Isopropyl myristate, liquid paraffin, soybean oil (35 – 39%, w/w) | O/W | Rotor/stator homogenizer operating at 10,000 rpm for 5 min | NA | NA | Stable formulation with 25% (w/w) of βCD |
[
|
| Tadalafil* | αCD βCD | 2 – 6% (w/V) | Purified water (90 or 80%, v/v) | Sweet almond oil (10 or 20%, V/V) | O/W | Overhead stirrer operating at 6,000 rpm for 5 min followed by freeze-drying with addition of gelatine and mannitol to obtain tablets | 0.45 and 0.62 μm for drug free and drug loaded formulation | Solid upon freeze-drying | Emulsions formulated with βCD showed superior stability to those with αCD |
[
|
Miconazole nitrate or Miconazoctylium bromide (1%, w/w) | βCD | 10% (w/w) | Purified water (45%, w/w) | Liquid paraffin, Carvacrol or terpinene-4-ol (45%, w/w) | O/W | Vortex stirrer operating at 3200 rpm for 1.5 min | 35, 39 and 36 μm for Liquid paraffin, carvacrol or terpinene-4-ol, respectively | Cream | Temperature and oil-type dependent, (liquid paraffin < terpinene-4-il < carvacrol) |
[
|
| Miconazoctylium bromide (1%, w/w) and undecylenic acid (10% w/w) | βCD | 10% (w/w) | Purified water (45% w/w) | Liquid paraffin, carvacrol, or terpinene-4-ol (45%, w/w) | O/W | Vortex stirrer operating at 3200 rpm for 1.5 min | 13 – 39 µm depending on the content, where drug loaded samples showed smaller droplet size (13–18 µm) | Creams for liquid parafilm and carvacrol samples; Lotion for terpinene-4-ol based emulsion | NA |
[
|
Miconazole, miconazole nitrate or econazole nitrate (1 or 2%, w/w) | αCD/PEG hydrogel | 2.9/80.9/16.2 PEG 20,000 to water to αCD weight ratio | 49.33% (w/w) of αCD/PEG hydrogel preserved with 0.2% (w/w) of benzoic acid | Liquid paraffin (49.47%, w/w) | O/W | Rotor/stator homogenizer operating at 11,500 rpm for 3 min | 3.8–5.9 μm depending on the drug type | Cream | Excellent stability with less than 0.5% of the water phase separated after 12 months |
[
|
| Lavander essential oil | βCD/Tween 20 nanocrystals formed at 1:0.3 weight ration | ** | αCD/PEG 2 000 hydrogel (1:1) ** | Lavender essential oil ** | O/W | Nanocrystals were first prepared by moderate mixing at 300 rpm for 3 h, followed by oil addition and rotor/stator homogenization at 10,000 rpm for 5 min | 205 nm | NA | Stable over 60 days |
[
|
|
| Span 80 and βCD | Span 80 at 10% (V/V) in W 1 , βCD at 5% (w/V) in W 2 |
W
1
–
W 2 – βCD solution (40%, V/V) | Canola oil (36%, V/V) | W 1 /O/W 2 | W 1 /O emulsion was homogenised at 6,000 rpm for 4 min W 1 /O/W 2 emulsion was homogenised at 8,000 rpm for 4 min using rotating blade homogenizer | 4.43 – 13.04 μM | NA | Moderately stable |
[
|
|
| Span 80 and βCD | Span 80 at 10% (V/V) in W 1 , βCD at 2.5% (w/V) in W 2 |
W
1
–
W 2 βCD solution (40–60%, V/V | Corn oil | W 1 /O/W 2 |
W
1
/O emulsion was homogenised at 3226 ×
W
1
/O/W
2
emulsion was homogenised at 3226 ×
| 2.9 – 3.3 μm, depending on the composition | NA | NA |
[
|
Lutein (0.5 mg/mL) | βCD | 0.5 – 2.5% (w/V) | Purified water | Sunflower oil (60 – 80%, V/V) | High internal phase O/W emulsion | Rotor/stator homogenizer operating at 15.000 rpm for 3 min | 6.31 ± 0.61 at 2.5% (w/V) of βCD | NA | Dependent on βCD concentration |
[
|
NA Not analysed
*The drug was dissolved in an optimal Pickering emulsion formulation at 15 mg/mL. The emulsion was freeze-dried to yield tablets containing 10 mg drug per tablet
**The author did not provide data about the added quantity of water, so the exact composition of the samples cannot be deduced